

BAGER,ARWA

DOB: 03/31/1981 Sex: F Phone: (305) 788-5319 Patient ID: 10513 Age: 42 Fasting: Y Specimen: MZ938634E Requisition: 0001736 Lab Reference ID: 51847 Report Status: FINAL / SEE REPORT Collected: 01/17/2024 07:00 Received: 01/17/2024 07:01 Reported: 01/21/2024 20:46 Client #: 73916914 TOLENTINO, JACLYN PARSLEY HEALTH LA 8550 SANTA MONICA BLVD FL 2 WEST HOLLYWOOD, CA 90069-4496 Phone: (833) 447-2775

FASTING:YES

Analyta

▲ HEMOGLOBIN A1c

| Analyte | value | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|--------------------------------------|
| ▲ HEMOGLOBIN A1c | 5.7 H | Reference Range: <5.7 % of total Hgb |
| For someone without known diabetes, a hemoglobin A1c value between 5.7% and 6.4% is consistent with prediabetes and should be confirmed with a follow-up test. | | |
| For someone with known diabetes, a value <7% indicates that their diabetes is well controlled. Alc targets should be individualized based on duration of diabetes, age, comorbid conditions, and other considerations. | | |
| This assay result is consistent with an increased risk of diabetes. | | |
| Currently, no consensus exists regarding use of hemoglobin A1c for diagnosis of diabetes for children. | | |

Value

COMMENT

purposes.

HbA1c performed on Roche platform. Effective 10/16/23 a change in test platforms may have shifted HbA1c results compared to historical results.

▲ MAGNESIUM, RBC

| Analyte | Value | |
|------------------------------------------------------------------------------------------------------------|-------|--------------------------------|
| ▲ MAGNESIUM, RBC | 7.0 H | Reference Range: 4.0-6.4 mg/dL |
| THIS RESULT HAS BEEN VERIFIED BY REPEAT ANALYSIS. | | |
| This test was developed and its analytical performance | | |
| characteristics have been determined by Quest | | |
| Diagnostics Nichols Institute Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug | | |
| Administration. This assay has been validated pursuant | | |
| to the CLIA regulations and is used for clinical | | |

▲ CBC (INCLUDES DIFF/PLT)

| Analyte | Value |
|------------------------|--------------------------------------------|
| WHITE BLOOD CELL COUNT | 10.5 Reference Range: 3.8-10.8 Thousand/uL |
| RED BLOOD CELL COUNT | 4.50 Reference Range: 3.80-5.10 Million/uL |
| HEMOGLOBIN | 12.4 Reference Range: 11.7-15.5 g/dL |
| HEMATOCRIT | 38.9 Reference Range: 35.0-45.0 % |
| MCV | 86.4 Reference Range: 80.0-100.0 fL |
| MCH | 27.6 Reference Range: 27.0-33.0 pg |

| ▲ MCHC | 31.9 L Reference Range: 32.0-36.0 g/dL |
|----------------------|--------------------------------------------|
| RDW | 12.6 Reference Range: 11.0-15.0 % |
| ▲ PLATELET COUNT | 460 H Reference Range: 140-400 Thousand/uL |
| MPV | 9.3 Reference Range: 7.5-12.5 fL |
| ABSOLUTE NEUTROPHILS | 6279 Reference Range: 1500-7800 cells/uL |
| ABSOLUTE LYMPHOCYTES | 3171 Reference Range: 850-3900 cells/uL |
| ABSOLUTE MONOCYTES | 515 Reference Range: 200-950 cells/uL |
| ABSOLUTE EOSINOPHILS | 462 Reference Range: 15-500 cells/uL |
| ABSOLUTE BASOPHILS | 74 Reference Range: 0-200 cells/uL |
| NEUTROPHILS | 59.8 % |
| LYMPHOCYTES | 30.2 % |
| MONOCYTES | 4.9 % |
| EOSINOPHILS | 4.4 % |
| BASOPHILS | 0.7 % |

▲ VITAMIN B12

| Analyte | Value |
|---------------|----------------------------------------|
| ▲ VITAMIN B12 | 1993 H Reference Range: 200-1100 pg/mL |

COMPREHENSIVE METABOLIC PANEL

| Analyte | Value | |
|--------------------------------------------------------------|-----------|------------------------------------------|
| GLUCOSE | 96 | Reference Range: 65-99 mg/dL |
| Fasting reference interval | | |
| UREA NITROGEN (BUN) | 10 | Reference Range: 7-25 mg/dL |
| CREATININE | 0.72 | Reference Range: 0.50-0.99 mg/dL |
| EGFR | 107 | Reference Range: > OR = 60 mL/min/1.73m2 |
| BUN/CREATININE RATIO | SEE NOTE: | Reference Range: 6-22 (calc) |
| Not Reported: BUN and Creatinine are within reference range. | | |
| SODIUM | 140 | Reference Range: 135-146 mmol/L |
| POTASSIUM | 4.4 | Reference Range: 3.5-5.3 mmol/L |
| CHLORIDE | 102 | Reference Range: 98-110 mmol/L |
| CARBON DIOXIDE | 26 | Reference Range: 20-32 mmol/L |
| CALCIUM | 9.9 | Reference Range: 8.6-10.2 mg/dL |
| PROTEIN, TOTAL | 7.0 | Reference Range: 6.1-8.1 g/dL |
| ALBUMIN | 4.4 | Reference Range: 3.6-5.1 g/dL |
| GLOBULIN | 2.6 | Reference Range: 1.9-3.7 g/dL (calc) |
| ALBUMIN/GLOBULIN RATIO | 1.7 | Reference Range: 1.0-2.5 (calc) |
| BILIRUBIN, TOTAL | 0.4 | Reference Range: 0.2-1.2 mg/dL |
| ALKALINE PHOSPHATASE | 49 | Reference Range: 31-125 U/L |
| | | |

| AST | 14 | Reference Range: 10-30 U/L |
|-----|----|----------------------------|
| ALT | 11 | Reference Range: 6-29 U/L |

VITAMIN D,25-OH,TOTAL,IA

| Analyte | | Value | |
|------------------------|--------------------------------------|-------|-------------------------------|
| VITAMIN D,25-OH,TOTAL, | IA . | 86 | Reference Range: 30-100 ng/mL |
| Vitamin D Status | 25-OH Vitamin D: | | |
| Deficiency: | <20 ng/mL | | |
| Insufficiency: | 20 - 29 ng/mL | | |
| Optimal: | > or = 30 ng/mL | | |
| | esting on patients on | | |
| | nd patients for whom quantitation | | |
| | ns is required, the QuestAssureD(TM) | | |
| 25-OH VIT D, (D2,D3) | LC/MS/MS is recommended: order | | |
| code 92888 (patients | >2yrs). | | |

COMMENT

See Note 1

TSH

| Analyte | | Value | | |
|-------------------|-----------|-------|-------|--|
| TSH | | 2.94 | mIU/L | |
| Reference Range | | | | |
| > or = 20 Years (| 0.40-4.50 | | | |
| Pregnancy Ram | nges | | | |
| First trimester | 0.26-2.66 | | | |
| Second trimester | 0.55-2.73 | | | |
| Third trimester | 0.43-2.91 | | | |

T4, FREE

| Analyte | Value | |
|----------|-------|--------------------------------|
| T4, FREE | 1.5 | Reference Range: 0.8-1.8 ng/dL |

T3, FREE

| Analyte | Value |
|----------|------------------------------------|
| T3, FREE | 3.3 Reference Range: 2.3-4.2 pg/mL |

T3 REVERSE, LC/MS/MS

| Analyte | Value | |
|----------------------|-------|----------------------------------------|
| T3 REVERSE, LC/MS/MS | 22 | Reference Range: 8-25 ng/dL See Note 1 |

THYROGLOBULIN ANTIBODIES

| Analyte | Value | |
|--------------------------|-------|---------------------------------|
| THYROGLOBULIN ANTIBODIES | <1 | Reference Range: < or = 1 IU/mL |

THYROID PEROXIDASE ANTIBODIES

| Analyte | Value | |
|-------------------------------|-------|---------------------------|
| THYROID PEROXIDASE ANTIBODIES | <1 | Reference Range: <9 IU/mL |

MERCURY, BLOOD

| Analyte | Value | |
|----------------|-------|----------------------------------------|
| MERCURY, BLOOD | <4 | Reference Range: <=10 mcg/L See Note 1 |

FERRITIN

| Analyte | Value | |
|----------|-------|-------------------------------|
| FERRITIN | 21 | Reference Range: 16-232 ng/mL |

FOLATE, RBC

| Analyte | Value | |
|-------------|-------|---------------------------------|
| FOLATE, RBC | 669 | Reference Range: >280 ng/mL RBC |

INSULIN

| Analyte | | Value | |
|-------------------------------|----------------------------------------------------------------------------------------------------------------------|-------------|--|
| INSULIN | | 14.3 uIU/mL | |
| Reference Ran | nge < or = 18.4 | | |
| Risk: | | | |
| Optimal | < or = 18.4 | | |
| Moderate | NA | | |
| High | >18.4 | | |
| cut points (o are based on | vascular event risk category optimal, moderate, high) Insulin Reference Interval ormed at Quest Diagnostics | | |

LEAD (VENOUS)

| Analyte | Value | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|------------------------------|
| LEAD (VENOUS) | <1.0 | Reference Range: <3.5 mcg/dL |
| See Note 2 | | |
| Note 1 | | |
| For additional information, please refer to http://education.QuestDiagnostics.com/faq/FAQ199 (This link is being provided for informational/educational purposes only.) | | |
| Note 2 | | |
| This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. | | |

$\mathsf{OMEGACHECK}^{\texttt{®}}$

| Analyte | Value |
|---------|-------|
| | |

EPA+DPA+DHA

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Cardiometabolic Center of Excellence at Cleveland HeartLab. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Increasing blood levels of long-chain n-3 fatty acids are associated with a lower risk of sudden cardiac death (1). Based on the top (75th percentile) and bottom (25th percentile) quartiles of the CHL reference population, the following relative risk categories were established for OmegaCheck: A cut-off of >=5.5% by wt defines a population at optimal relative risk, 3.8-5.4% by wt defines a population at moderate relative risk, and <=3.7% by wt defines a population at high relative risk of sudden cardiac death. The totality of the scientific evidence demonstrates that when consumption of fish oils is limited to 3 g/day or less of EPA and DHA, there is no significant risk for increased bleeding time beyond the normal range. A daily dosage of 1 gram of EPA and DHA lowers the circulating triglycerides by about 7-10% within 2 to 3 weeks. (Reference: 1-Albert et al. NEJM. 2002; 346: 1113-1118).

6.0 Reference Range: >5.4 % by wt

| ARACHIDONIC ACID/EPA RATIO | 6.2 | Reference Range: 3.7-40.7 |
|------------------------------------------------------------------------------------------------------------------------|------|------------------------------------|
| OMEGA-6/OMEGA-3 RATIO | 6.6 | Reference Range: 3.7-14.4 |
| OMEGA-3 TOTAL | 6.0 | % by wt |
| ЕРА | 1.4 | Reference Range: 0.2-2.3 % by wt |
| DPA | 1.3 | Reference Range: 0.8-1.8 % by wt |
| DHA | 3.3 | Reference Range: 1.4-5.1 % by wt |
| OMEGA-6 TOTAL | 40.2 | % by wt |
| Cleveland HeartLab measures a number of omega-6 fatty acids with AA and LA being the two most abundant forms reported. | | |
| ARACHIDONIC ACID | 8.6 | Reference Range: 8.6-15.6 % by wt |
| LINOLEIC ACID | 29.2 | Reference Range: 18.6-29.5 % by wt |

Note 1

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Performing Sites

AMD Quest Diagnostics/Nichols Chantilly-Chantilly VA, 14225 Newbrook Dr, Chantilly, VA 20151-2228 Laboratory Director: Patrick W Mason

MI Quest Diagnostics-Miami, 10200 Commerce Pkwy, Miramar, FL 33025-3938 Laboratory Director: Julie L Friedman, MD TP Quest Diagnostics-Tampa, 4225 E Fowler Ave, Tampa, FL 33617-2026 Laboratory Director: Weston H Rothrock MD Z4M Cleveland HeartLab Inc.-Cleveland HeartLab Inc., 6701 Carnegie Ave, Suite 500, Cleveland, OH 44103-4623 Laboratory Director: Mohammad Q Ansari

Key





These results have been sent to the person who ordered the tests. Your receipt of these results should not be viewed as medical advice and is not meant to replace discussion with your doctor or other healthcare professional.

Quest, Quest Diagnostics, the associated logo, Nichols Institute, Interactive Insights and all associated Quest Diagnostics marks are the registered trademarks of Quest Diagnostics. All third party marks - '8' and 'TM' - are the property of their respective owners. Privacy policy can be found at: http://questdiagnostics.com/home/privacy-policy/online-privacy.html . © 2022 Quest Diagnostics Incorporated, All rights reserved.

